Details of the Drug

General Information of Drug (ID: DMKMWQG)

• Drug Name: Olopatadine
• Synonyms: Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Allergic conjunctivitis	9A60.02	Approved	[1], [2]
Ocular allergy	4A81	Phase 3	[1], [2]

• Therapeutic Class: Antiallergic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 337.4
  Topological Polar Surface Area (xlogp); 1.5
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 9.7 +/- 4.4 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1.6 +/- 0.9 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
  Clearance: The apparent oral clearance of drug is 23.45 L/h [5]
  Elimination: About 70% and 17% of the oral dose was recovered in the urine and feces, respectively [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 +/- 1.2 hours [7]
  Metabolism: The drug is metabolized via the hepatic [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1058 micromolar/kg/day [8]
  Vd: The volume of distribution (Vd) of drug is 133.83 L [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 2 mg/mL [4]
• Chemical Identifiers:
  Formula: C21H23NO3
  IUPAC Name: 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
  Canonical SMILES: CN(C)CC/C=C\\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
  InChI: InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
  InChIKey: JBIMVDZLSHOPLA-LSCVHKIXSA-N
• Cross-matching ID:
  PubChem CID: 5281071
  ChEBI ID: CHEBI:94593
  CAS Number: 113806-05-6
  DrugBank ID: DB00768
  TTD ID: D05GPO
  VARIDT ID: DR01357
  INTEDE ID: DR1192

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Dimethylaniline oxidase 3 (FMO3) Main DME	DEP76YL	FMO3_HUMAN	Substrate	[]
Dimethylaniline oxidase 1 (FMO1) Main DME	DEJ73Q9	FMO1_HUMAN	Substrate	[]

Molecular Expression Atlas of This Drug

• The Studied Disease: Allergic conjunctivitis
• ICD Disease Classification: 9A60.02

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Olopatadine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Olopatadine and Oliceridine.	Acute pain [MG31]	[34]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Olopatadine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[34]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[34]
Tripelennamine	DMZBU15	Moderate	Additive CNS depression effects by the combination of Olopatadine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[34]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive CNS depression effects by the combination of Olopatadine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[34]
Trimethaphan	DMHF4IQ	Moderate	Additive CNS depression effects by the combination of Olopatadine and Trimethaphan.	Aneurysm/dissection [BD50]	[34]
Amyl nitrite	DMJKO05	Moderate	Additive CNS depression effects by the combination of Olopatadine and Amyl nitrite.	Angina pectoris [BA40]	[34]
Methylphenobarbital	DMDSWAG	Moderate	Additive CNS depression effects by the combination of Olopatadine and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[34]
Halazepam	DMPFWO6	Moderate	Additive CNS depression effects by the combination of Olopatadine and Halazepam.	Anxiety disorder [6B00-6B0Z]	[34]
Oxazepam	DMXNZM4	Moderate	Additive CNS depression effects by the combination of Olopatadine and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[34]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Olopatadine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[34]
Retigabine	DMGNYIH	Moderate	Additive CNS depression effects by the combination of Olopatadine and Retigabine.	Behcet disease [4A62]	[34]
Cariprazine	DMJYDVK	Moderate	Additive CNS depression effects by the combination of Olopatadine and Cariprazine.	Bipolar disorder [6A60]	[34]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Olopatadine and Loperamide.	Bowel habit change [ME05]	[34]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Olopatadine and Dihydrocodeine.	Chronic pain [MG30]	[34]
Levetiracetam	DMTGDN8	Moderate	Additive CNS depression effects by the combination of Olopatadine and Levetiracetam.	Chronic pain [MG30]	[34]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Olopatadine and Propofol.	Corneal disease [9A76-9A78]	[34]
Ketamine	DMT5HA4	Moderate	Additive CNS depression effects by the combination of Olopatadine and Ketamine.	Corneal disease [9A76-9A78]	[34]
Alfentanil	DMVO0UB	Moderate	Additive CNS depression effects by the combination of Olopatadine and Alfentanil.	Corneal disease [9A76-9A78]	[34]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Olopatadine and Remifentanil.	Corneal disease [9A76-9A78]	[34]
Chlophedianol	DMXGJEI	Moderate	Additive CNS depression effects by the combination of Olopatadine and Chlophedianol.	Cough [MD12]	[34]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Olopatadine and Ethanol.	Cystitis [GC00]	[34]
Sertraline	DM0FB1J	Moderate	Additive CNS depression effects by the combination of Olopatadine and Sertraline.	Depression [6A70-6A7Z]	[34]
Cyclobenzaprine	DM1YBRM	Moderate	Additive CNS depression effects by the combination of Olopatadine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[34]
Nefazodone	DM4ZS8M	Moderate	Additive CNS depression effects by the combination of Olopatadine and Nefazodone.	Depression [6A70-6A7Z]	[34]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Olopatadine and Isocarboxazid.	Depression [6A70-6A7Z]	[34]
Escitalopram	DMFK9HG	Moderate	Additive CNS depression effects by the combination of Olopatadine and Escitalopram.	Depression [6A70-6A7Z]	[34]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Olopatadine and Desvenlafaxine.	Depression [6A70-6A7Z]	[34]
OPC-34712	DMHG57U	Moderate	Additive CNS depression effects by the combination of Olopatadine and OPC-34712.	Depression [6A70-6A7Z]	[34]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenelzine.	Depression [6A70-6A7Z]	[34]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Olopatadine and Clomipramine.	Depression [6A70-6A7Z]	[34]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Olopatadine and Doxepin.	Depression [6A70-6A7Z]	[34]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Olopatadine and Maprotiline.	Depression [6A70-6A7Z]	[34]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Olopatadine and Esketamine.	Depression [6A70-6A7Z]	[34]
Heroin diacetylmorphine	DMDBWHY	Moderate	Additive CNS depression effects by the combination of Olopatadine and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[34]
Tetrabenazine	DMYWQ0O	Moderate	Additive CNS depression effects by the combination of Olopatadine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[34]
Diazepam	DM08E9O	Moderate	Additive CNS depression effects by the combination of Olopatadine and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[34]
Zonisamide	DM0DTF7	Moderate	Additive CNS depression effects by the combination of Olopatadine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[34]
Primidone	DM0WX6I	Moderate	Additive CNS depression effects by the combination of Olopatadine and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[34]
Felbamate	DM1V5ZS	Moderate	Additive CNS depression effects by the combination of Olopatadine and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[34]
Methsuximide	DM6L5VO	Moderate	Additive CNS depression effects by the combination of Olopatadine and Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[34]
Gabapentin	DM6T924	Moderate	Additive CNS depression effects by the combination of Olopatadine and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cenobamate	DMGOVHA	Moderate	Additive CNS depression effects by the combination of Olopatadine and Cenobamate.	Epilepsy/seizure [8A61-8A6Z]	[34]
Tiagabine	DMKSQG0	Moderate	Additive CNS depression effects by the combination of Olopatadine and Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[34]
Phenacemide	DMOHS9P	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[34]
Fosphenytoin	DMOX3LB	Moderate	Additive CNS depression effects by the combination of Olopatadine and Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[34]
Brivaracetam	DMSEPK8	Moderate	Additive CNS depression effects by the combination of Olopatadine and Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[34]
Clonazepam	DMTO13J	Moderate	Additive CNS depression effects by the combination of Olopatadine and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[34]
Rufinamide	DMWE60C	Moderate	Additive CNS depression effects by the combination of Olopatadine and Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[34]
Phenobarbital	DMXZOCG	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[34]
Vigabatrin	DMYT0OG	Moderate	Additive CNS depression effects by the combination of Olopatadine and Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Olopatadine and Cannabidiol.	Epileptic encephalopathy [8A62]	[34]
Phenoxybenzamine	DM8KSQH	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenoxybenzamine.	Essential hypertension [BA00]	[34]
Dantrolene	DM1D8XY	Moderate	Additive CNS depression effects by the combination of Olopatadine and Dantrolene.	Fever [MG26]	[34]
Chlorothiazide	DMLHESP	Moderate	Additive CNS depression effects by the combination of Olopatadine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[34]
Hydroflumethiazide	DMVPUQI	Moderate	Additive CNS depression effects by the combination of Olopatadine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[34]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive CNS depression effects by the combination of Olopatadine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[34]
Eprosartan	DM07K2I	Moderate	Additive CNS depression effects by the combination of Olopatadine and Eprosartan.	Hypertension [BA00-BA04]	[34]
Captopril	DM458UM	Moderate	Additive CNS depression effects by the combination of Olopatadine and Captopril.	Hypertension [BA00-BA04]	[34]
Indapamide	DMGN1PW	Moderate	Additive CNS depression effects by the combination of Olopatadine and Indapamide.	Hypertension [BA00-BA04]	[34]
Diazoxide	DML1538	Moderate	Additive CNS depression effects by the combination of Olopatadine and Diazoxide.	Hypertension [BA00-BA04]	[34]
Perindopril	DMOPZDT	Moderate	Additive CNS depression effects by the combination of Olopatadine and Perindopril.	Hypertension [BA00-BA04]	[34]
Quinapril	DMR8H31	Moderate	Additive CNS depression effects by the combination of Olopatadine and Quinapril.	Hypertension [BA00-BA04]	[34]
Telmisartan	DMS3GX2	Moderate	Additive CNS depression effects by the combination of Olopatadine and Telmisartan.	Hypertension [BA00-BA04]	[34]
Irbesartan	DMTP1DC	Moderate	Additive CNS depression effects by the combination of Olopatadine and Irbesartan.	Hypertension [BA00-BA04]	[34]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive CNS depression effects by the combination of Olopatadine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[34]
Belladonna	DM2RBWK	Moderate	Additive CNS depression effects by the combination of Olopatadine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[34]
Suvorexant	DM0E6S3	Moderate	Additive CNS depression effects by the combination of Olopatadine and Suvorexant.	Insomnia [7A00-7A0Z]	[34]
Amobarbital	DM0GQ8N	Moderate	Additive CNS depression effects by the combination of Olopatadine and Amobarbital.	Insomnia [7A00-7A0Z]	[34]
Ramelteon	DM7IW9J	Moderate	Additive CNS depression effects by the combination of Olopatadine and Ramelteon.	Insomnia [7A00-7A0Z]	[34]
Triazolam	DMETYK5	Moderate	Additive CNS depression effects by the combination of Olopatadine and Triazolam.	Insomnia [7A00-7A0Z]	[34]
Zaleplon	DMGFWSM	Moderate	Additive CNS depression effects by the combination of Olopatadine and Zaleplon.	Insomnia [7A00-7A0Z]	[34]
Propiomazine	DMKY8V1	Moderate	Additive CNS depression effects by the combination of Olopatadine and Propiomazine.	Insomnia [7A00-7A0Z]	[34]
Tasimelteon	DMLOQ1V	Moderate	Additive CNS depression effects by the combination of Olopatadine and Tasimelteon.	Insomnia [7A00-7A0Z]	[34]
Paraldehyde	DMOC1BX	Moderate	Additive CNS depression effects by the combination of Olopatadine and Paraldehyde.	Insomnia [7A00-7A0Z]	[34]
ITI-007	DMUQ1DO	Moderate	Additive CNS depression effects by the combination of Olopatadine and ITI-007.	Insomnia [7A00-7A0Z]	[34]
Quazepam	DMY4D87	Moderate	Additive CNS depression effects by the combination of Olopatadine and Quazepam.	Insomnia [7A00-7A0Z]	[34]
Estazolam	DMZGXUM	Moderate	Additive CNS depression effects by the combination of Olopatadine and Estazolam.	Insomnia [7A00-7A0Z]	[34]
Remimazolam	DMLVSYX	Moderate	Additive CNS depression effects by the combination of Olopatadine and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[34]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Olopatadine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[35]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Olopatadine and Lasmiditan.	Migraine [8A80]	[34]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Olopatadine and Flibanserin.	Mood disorder [6A60-6E23]	[34]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Olopatadine and Thalidomide.	Multiple myeloma [2A83]	[34]
Azacitidine	DMTA5OE	Moderate	Additive CNS depression effects by the combination of Olopatadine and Azacitidine.	Myelodysplastic syndrome [2A37]	[34]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Olopatadine and Phenindamine.	Nasopharyngitis [CA00]	[34]
Dimenhydrinate	DM264B3	Moderate	Additive CNS depression effects by the combination of Olopatadine and Dimenhydrinate.	Nausea/vomiting [MD90]	[34]
Promethazine	DM6I5GR	Moderate	Additive CNS depression effects by the combination of Olopatadine and Promethazine.	Nausea/vomiting [MD90]	[34]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Olopatadine and Cyclizine.	Nausea/vomiting [MD90]	[34]
Metoclopramide	DMFA5MY	Moderate	Additive CNS depression effects by the combination of Olopatadine and Metoclopramide.	Nausea/vomiting [MD90]	[34]
Bupropion	DM5PCS7	Moderate	Additive CNS depression effects by the combination of Olopatadine and Bupropion.	Nicotine use disorder [6C4A]	[34]
Sibutramine	DMFJTDI	Moderate	Additive CNS depression effects by the combination of Olopatadine and Sibutramine.	Obesity [5B80-5B81]	[34]
Polythiazide	DMCH80F	Moderate	Additive CNS depression effects by the combination of Olopatadine and Polythiazide.	Oedema [MG29]	[34]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Olopatadine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[34]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Olopatadine and Apraclonidine.	Optic nerve disorder [9C40]	[36]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Olopatadine and Oxymorphone.	Pain [MG30-MG3Z]	[34]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Olopatadine and Levorphanol.	Pain [MG30-MG3Z]	[34]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Olopatadine and Dezocine.	Pain [MG30-MG3Z]	[34]
Flavoxate	DMKV4NL	Moderate	Additive CNS depression effects by the combination of Olopatadine and Flavoxate.	Pain [MG30-MG3Z]	[34]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Olopatadine and Nalbuphine.	Pain [MG30-MG3Z]	[34]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Olopatadine and Buprenorphine.	Pain [MG30-MG3Z]	[34]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Olopatadine and Hydrocodone.	Pain [MG30-MG3Z]	[34]
Ziconotide	DMSLJP4	Moderate	Additive CNS depression effects by the combination of Olopatadine and Ziconotide.	Pain [MG30-MG3Z]	[34]
Opicapone	DM1BKA6	Moderate	Additive CNS depression effects by the combination of Olopatadine and Opicapone.	Parkinsonism [8A00]	[34]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Olopatadine and Biperiden.	Parkinsonism [8A00]	[34]
Terazosin	DM3JCVS	Moderate	Additive CNS depression effects by the combination of Olopatadine and Terazosin.	Prostate hyperplasia [GA90]	[34]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Olopatadine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[34]
Quetiapine	DM1N62C	Moderate	Additive CNS depression effects by the combination of Olopatadine and Quetiapine.	Schizophrenia [6A20]	[34]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Olopatadine and Mesoridazine.	Schizophrenia [6A20]	[34]
Aripiprazole	DM3NUMH	Moderate	Additive CNS depression effects by the combination of Olopatadine and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Moderate	Additive CNS depression effects by the combination of Olopatadine and Iloperidone.	Schizophrenia [6A20]	[34]
Paliperidone	DM7NPJS	Moderate	Additive CNS depression effects by the combination of Olopatadine and Paliperidone.	Schizophrenia [6A20]	[34]
Perphenazine	DMA4MRX	Moderate	Additive CNS depression effects by the combination of Olopatadine and Perphenazine.	Schizophrenia [6A20]	[34]
Molindone	DMAH70G	Moderate	Additive CNS depression effects by the combination of Olopatadine and Molindone.	Schizophrenia [6A20]	[34]
Thiothixene	DMDINC4	Moderate	Additive CNS depression effects by the combination of Olopatadine and Thiothixene.	Schizophrenia [6A20]	[34]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Olopatadine and Trifluoperazine.	Schizophrenia [6A20]	[34]
Asenapine	DMSQZE2	Moderate	Additive CNS depression effects by the combination of Olopatadine and Asenapine.	Schizophrenia [6A20]	[34]
Fentanyl	DM8WAHT	Moderate	Additive CNS depression effects by the combination of Olopatadine and Fentanyl.	Sensation disturbance [MB40]	[34]
Disulfiram	DMCL2OK	Moderate	Additive CNS depression effects by the combination of Olopatadine and Disulfiram.	Substance abuse [6C40]	[34]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Olopatadine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[34]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Olopatadine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[34]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Olopatadine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[34]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Olopatadine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[34]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Olopatadine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[34]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7249).
• [2] Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
• [3] FDA Approved Drug Products: PAZEO (olopatadine hydrochloride) ophthalmic solution
• [4] BDDCS applied to over 900 drugs
• [5] Chu NN, Chen WL, Xu HR, Li XN: Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Clin Drug Investig. 2009;29(7):451-457. doi: 10.2165/00044011-200929070-00003.
• [6] FDA Approved Drug Products: PATANASE (olopatadine hydrochloride) Nasal Spray
• [7] Opatanol, INN-olopatadine - European Medicines Agency - Europa EU
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [10] Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
• [11] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [12] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [13] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [14] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [15] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [16] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [17] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [18] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [19] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [20] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [21] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [22] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [23] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [24] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [25] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [26] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [27] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [28] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [29] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [30] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [31] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [32] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [33] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
• [34] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [35] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [36] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.